Arama Sonuçları - Alan F. List

Sonuçları Daraltın
  1. 1
    Vascular Endothelial Growth Factor Signaling Pathway as an Emerging Target in Hematologic Malignancies

    Vascular Endothelial Growth Factor Signaling Pathway as an Emerging Target in Hematologic Malignancies Yazar: Alan F. List

    Baskı/Yayın Bilgisi 2001
    Tam Metin Erişim Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  2. 2
    Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies

    Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies Yazar: Daruka Mahadevan, Alan F. List

    Baskı/Yayın Bilgisi 2004
    Tam Metin Erişim Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  3. 3
    The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes

    The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes Yazar: David A. Sallman, Alan F. List

    Baskı/Yayın Bilgisi 2019
    Tam Metin Erişim Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  4. 4
    When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia

    When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia Yazar: Markus Ball, Alan F. List, Eric Padron

    Baskı/Yayın Bilgisi 2016
    Tam Metin Erişim Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  5. 5
    Molecular pathogenesis of myelodysplastic syndromes with deletion 5q

    Molecular pathogenesis of myelodysplastic syndromes with deletion 5q Yazar: Jung-Hoon Lee, Alan F. List, David A. Sallman

    Baskı/Yayın Bilgisi 2018
    Tam Metin Erişim Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  6. 6
    Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype

    Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype Yazar: David A. Sallman, Thomas Cluzeau, Ashley A. Basiorka, Alan F. List

    Baskı/Yayın Bilgisi 2016
    Tam Metin Erişim Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  7. 7
    Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries

    Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries Yazar: Christopher R. Cogle, Benjamin M. Craig, Dana E. Rollison, Alan F. List

    Baskı/Yayın Bilgisi 2011
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  8. 8
    Underreporting of Myeloid Malignancies by United States Cancer Registries

    Underreporting of Myeloid Malignancies by United States Cancer Registries Yazar: Benjamin M. Craig, Dana E. Rollison, Alan F. List, Christopher R. Cogle

    Baskı/Yayın Bilgisi 2012
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  9. 9
    Myelodysplastic Syndromes

    Myelodysplastic Syndromes Yazar: Alan F. List, James W. Vardiman, Jean–Pierre J. Issa, Theo deWitte

    Baskı/Yayın Bilgisi 2004
    Tam Metin Erişim Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  10. 10
    Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes

    Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes Yazar: Mikkael A. Sekeres, Jaroslaw P. Maciejewski, Aristoteles Giagounidis, Kenton Wride, Robert Knight, Azra Raza, Alan F. List

    Baskı/Yayın Bilgisi 2008
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  11. 11
    Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations

    Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations Yazar: M Russell, Alan F. List, Paul A. Greenberg, S Woodward, B Glinsmann, Evan Parganas, James Ihle, Raymond Taetle

    Baskı/Yayın Bilgisi 1994
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  12. 12
    <scp>WT</scp>1 vaccination in <scp>AML</scp> and <scp>MDS</scp>: A pilot trial with synthetic analog peptides

    <scp>WT</scp>1 vaccination in <scp>AML</scp> and <scp>MDS</scp>: A pilot trial with synthetic analog peptides Yazar: Jason Brayer, Jeffrey E. Lancet, John J. Powers, Alan F. List, Lodovico Balducci, Rami S. Komrokji, Javier Pinilla‐Ibarz

    Baskı/Yayın Bilgisi 2015
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  13. 13
    Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome

    Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome Yazar: Celeste M. Bello, Daohai Yu, Rami S. Komrokji, Weiwei Zhu, Gene A. Wetzstein, Alan F. List, Jeffrey E. Lancet

    Baskı/Yayın Bilgisi 2010
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  14. 14
    Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS

    Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS Yazar: Yang Mei, Baobing Zhao, Ashley A. Basiorka, Jing Yang, Lan Cao, J Zhang, Alan F. List, Peng Ji

    Baskı/Yayın Bilgisi 2017
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  15. 15
    Phase <scp>I</scp> clinical trial of oral rigosertib in patients with myelodysplastic syndromes

    Phase <scp>I</scp> clinical trial of oral rigosertib in patients with myelodysplastic syndromes Yazar: Rami S. Komrokji, Azra Raza, Jeffrey E. Lancet, Chen Ren, David R. Taft, Manoj Maniar, François Wilhelm, Alan F. List

    Baskı/Yayın Bilgisi 2013
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  16. 16
    Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes

    Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes Yazar: William Bellamy, Lynne Richter, Davuud Sirjani, Concepcion Roxas, Betty Glinsmann‐Gibson, Y Frutiger, Thomas M. Grogan, Alan F. List

    Baskı/Yayın Bilgisi 2001
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  17. 17
    Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome

    Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome Yazar: Rami S. Komrokji, Jeffrey E. Lancet, Arlene S. Swern, Nianhang Chen, Jennifer Paleveda, Richard M. Lush, Hussain I. Saba, Alan F. List

    Baskı/Yayın Bilgisi 2012
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  18. 18
    Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys

    Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys Yazar: Mikkael A. Sekeres, W. Marieke Schoonen, Hagop M. Kantarjian, Alan F. List, Jon P. Fryzek, Ronald Paquette, Jaroslaw P. Maciejewski

    Baskı/Yayın Bilgisi 2008
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  19. 19
    Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells

    Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells Yazar: Sangkil Nam, Ann H. Williams, Adina Vultur, Alan F. List, Kapil N. Bhalla, David Smith, Francis Y. Lee, Richard Jove

    Baskı/Yayın Bilgisi 2007
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  20. 20
    Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis

    Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis Yazar: Andrea Kuendgen, Michael Lauseker, Alan F. List, Pierre Fenaux, Aristoteles Giagounidis, Nancy A. Brandenburg, Jay T. Backstrom, Axel Glasmacher, Joerg Hasford, Ulrich Germing

    Baskı/Yayın Bilgisi 2012
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:

Arama Araçları: